You are here: Fairness.com > Resources > Health & Medicine > Health Care Business > Pharmaceutical / Drug / Biotech

Pharmaceutical / Drug / Biotech

Search only Pharmaceutical / Drug / Biotech, and everything underneath:

Articles and Resources

263 Articles and Resources. Go to:  [Next 50]   [End]

Date	Fairness.com Resource	Read it at:
Dec 11, 2012	Scientists Propose Central Database for Disclosing Conflicts of Interest QUOTE: a lack of standardization in COI disclosures increases the administrative burden on physicians and increases the chances of being accused of incomplete and misleading statements. As a solution, their committee — facilitated by the Institute of Medicine — recommends the creation of a centralize database for the disclosure and reporting of interests.	Scholarly Kitchen
Nov 24, 2012	As drug industry’s influence over research grows, so does the potential for bias QUOTE: What only careful readers of the article would have gleaned is the extent of the financial connections between the drugmaker and the research.Whether these ties altered the report on Avandia may be impossible for readers to know. But while sorting through the data from more than 4,000 patients, the investigators missed hints of a danger that, when fully realized four years later, would lead to Avandia’s virtual disappearance from the United States: The drug raised the risk of heart attacks....	Washington Post
Mar 20, 2012	Generic Drugs Proving Resistant to Damage Suits QUOTE: Across the country, dozens of lawsuits against generic pharmaceutical companies are being dismissed because of a Supreme Court decision last year that said the companies did not have control over what their labels said and therefore could not be sued for failing to alert patients about the risks of taking their drugs. Now, what once seemed like a trivial detail — whether to take a generic or brand-name drug — has become the deciding factor in whether a patient can seek legal recourse from a drug company.	New York Times
Mar 19, 2012	A Drumbeat on Profit Takers QUOTE: Their joint crusade, stated repeatedly in editorials for the journal and since expanded in books and dozens of articles in the lay press, is against for-profit medicine, especially its ancillary profit centers of commercial insurance and drug manufacture — in Dr. Relman’s words, “the people who are making a zillion bucks out of the commercial exploitation of medicine.”	New York Times
Dec 22, 2011	In Treating Disabled, Potent Drugs and Few Rules QUOTE: psychotropic medications, which alter the brain’s chemistry, are often dispensed sloppily, without rigorous or regular review, by general practitioners with little expertise in the area. And low-level workers at state group homes are frequently given discretion to increase the medication “as needed,” despite their lack of significant training.	New York Times
Jul 28, 2011	Useless Studies, Real Harm (Op-Ed) QUOTE: In an age of for-profit clinical research, this is the new face of scandal. Pharmaceutical companies promote their drugs with pseudo-studies that have little if any scientific merit, and patients naïvely sign up, unaware of the ways in which they are being used.	New York Times
Jul 07, 2011	How Bright Promise in Cancer Testing Fell Apart QUOTE: as patients and their doctors try to make critical decisions about serious illnesses, they may be getting worthless information that is based on bad science. The scientific world is concerned enough that two prominent groups, the National Cancer Institute and the Institute of Medicine, have begun examining the Duke case; they hope to find new ways to evaluate claims based on emerging and complex analyses of patterns of genes and other molecules.	New York Times
Jul 04, 2011	Think Inside the Box QUOTE: Bombarded with pharmaceutical ads listing what seems like every conceivable side effect, American consumers might think they are already getting too much information. But they — and their doctors — are not getting what arguably matters most: independent, plain-English facts about the medication. Fortunately, there is a simple model for getting such information across.	New York Times
Jun 23, 2011	High Court sides with generic drug makers in narrow ruling QUOTE: The justices in a 5-4 ruling said generic drug companies do not share the same level of responsibility as makers of brand-name equivalents, to update their warning labels when significant new risks emerge.	CNN (Cable News Network)
Jun 04, 2011	Drug Makers’ Feared Enemy Switches Sides, as Their Lawyer QUOTE: a year and a half ago, Mr. Loucks, a Republican, left the United States attorney’s office in Boston after he was passed over for the top post and President Obama appointed a Democrat. Instead, Mr. Loucks joined Skadden, Arps last July, and has startled former allies by emerging in recent months as zealous a corporate defender as he was a prosecutor, complete with proposals seeking more lenient treatment for the medical companies he once vilified.	New York Times
May 13, 2011	Google Is Said to Have Broken Internal Rules on Drug Ads QUOTE: Google allowed rogue online pharmacies to advertise on its site in violation of its own advertising policies, according to one of the companies subpoenaed in the federal investigation of Google’s drug ad sales.	New York Times
Mar 10, 2011	U.S. Regulators and J.&J. Unit Reach a Deal on Plant Oversight QUOTE: Federal regulators reached an agreement on Thursday with a unit of Johnson & Johnson that would impose greater federal oversight at three manufacturing plants responsible for recalls of children’s Tylenol and many other popular over-the-counter medicines... Last year, the company’s (Johnson & Johnson) DePuy unit recalled two different hip implants, affecting tens of thousands of patients worldwide. Its Animas unit recalled tens of thousands of insulin pump cartridges last month because they had the potential to leak and deliver too little insulin, the company said.	New York Times
Oct 27, 2010	Glaxo to Pay $750 Million for Sale of Bad Products QUOTE: GlaxoSmithKline, the British drug giant, has agreed to pay $750 million to settle criminal and civil complaints that the company for years knowingly sold contaminated baby ointment and an ineffective antidepressant — the latest in a growing number of whistle-blower lawsuits that drug makers have settled with multimillion-dollar fines.	New York Times
May 27, 2010	F.D.A. Weighs Penalties in Drug Recall QUOTE: [The FDA] is considering further actions against McNeil Consumer Healthcare, the Johnson & Johnson unit, after a pattern of violations in manufacturing and quality control practices led to a number of recent recalls...	New York Times
May 27, 2010	Safety Rules Can’t Keep Up With Biotech Industry QUOTE: the estimated 232,000 employees in the nation’s most sophisticated biotechnology labs work amid imponderable hazards. And some critics say the modern biolab often has fewer federal safety regulations than a typical blue-collar factory.	New York Times
Mar 21, 2010	When drug makers' profits outweigh penalties QUOTE: As large as the penalties are for drug companies caught breaking the off-label law, the fines are tiny compared with the firms' annual revenue. The $2.3 billion in fines and penalties Pfizer paid for marketing Bextra and three other drugs cited in the Sept. 2 plea agreement for off-label uses amount to just 14 percent of its $16.8 billion in revenue from selling those medicines from 2001 to 2008.	Bloomberg News
Nov 21, 2009	Growth of counterfeit drugs sparks international response: Authorities in the U.S. and across the globe conduct raids this week to intercept fake medications. QUOTE: Counterfeit drugs are the latest -- and potentially most dangerous -- front in the long-running battle against intellectual-property crimes	Los Angeles Times
Nov 18, 2009	DNA Testing Firm Goes Bankrupt; Who Gets the Data? (Threat Level) QUOTE: An Icelandic firm that offers private DNA testing to customers has filed for bankruptcy in the U.S., raising privacy concerns about the fate of customer DNA samples and records, according to the Times of London.	Wired
Nov 14, 2009	In House Record, Many Spoke With One Voice: Lobbyists’ QUOTE: Statements by more than a dozen lawmakers were ghostwritten, in whole or in part, by Washington lobbyists working for Genentech, one of the world’s largest biotechnology companies.	New York Times
Oct 27, 2009	A dubious alternative: There's no evidence that homeopathic products can prevent flu QUOTE: Unlike vaccines or prescription or over-the-counter drugs, homeopathic medicines, which account for annual U.S. sales of more than $200 million, do not need to demonstrate safety or effectiveness...	Washington Post
Oct 22, 2009	Research Uproar at a Cancer Clinic QUOTE: community [research] centers may not always be adhering to the rigorous protocols of research medicine that the National Cancer Institute expects them to follow.	New York Times
Oct 08, 2009	How to Stop the Counterfeit-Medicine Drugs Trade QUOTE: According to the World Health Organization (WHO), more than 50% of drugs sold online have either been falsified or altered in some way.	Time Magazine
Oct 07, 2009	Personal genomics firms must come clean QUOTE: Companies that offer analyses of future health risks based on basic genetic tests should be more transparent about the limitations of their predictions, says genomics pioneer Craig Venter.	New Scientist
Oct 01, 2009	Bayer Labels’ Cancer-Fighting Claim Draws Suit QUOTE: A nonprofit group in Washington has filed a lawsuit against Bayer Healthcare charging that the company’s labels and commercials falsely claimed its One A Day multivitamins for men may reduce the risk of prostate cancer.	New York Times
Sep 24, 2009	F.D.A. Reveals It Fell to a Push by Lawmakers QUOTE: The Food and Drug Administration said Thursday that four New Jersey congressmen and its own former commissioner unduly influenced the process that led to its decision last year to approve a patch for injured knees, an approval it is now revisiting.	New York Times
Sep 21, 2009	Benefit and Doubt in Vaccine Additive QUOTE: Are Americans obligated to use an unproven vaccine to help protect people in other countries from the flu pandemic?	New York Times
Sep 15, 2009	Where Cancer Progress Is Rare, One Man Says No (Forty Years' War) QUOTE: cancer has proven difficult to crack, leading to frustration among executives and advocates who wonder why the Food and Drug Administration is not approving more drugs.	New York Times
Sep 10, 2009	Ghostwriting Is Called Rife in Medical Journals QUOTE: In the scientific literature, ghostwriting usually refers to medical writers, often sponsored by a drug or medical device company, who make major research or writing contributions to articles published under the names of academic authors. The concern... is that the work of industry-sponsored writers has the potential to introduce bias...	New York Times
Sep 04, 2009	Awareness: Clinical Trial Rule Is Widely Ignored (Vital Signs) QUOTE: Many researchers are ignoring a 2005 requirement that they register proposed clinical trials in a government database as a condition for publishing their results in medical journals.	New York Times
Sep 04, 2009	Ethics scrutiny needed for Chinese–European projects: Panel calls for joint advisory body to monitor research. QUOTE: Biomedical research collaborations between Europe and China need greater ethical oversight to combat unregulated stem-cell therapies and prevent the exploitation of clinical-trial participants.	Nature
Sep 03, 2009	Academic researchers receive on average $33k a year from the medical industry (60-Second Science Blog) QUOTE: researchers in the ivory towers—and labs—of U.S. universities receive an average of $33,417 of funding a year from medical device, pharmaceutical and other medical industry companies...	Scientific American
Sep 02, 2009	High Stakes for Merck in Litigation on Fosamax QUOTE: Drug executives, product liability lawyers and Wall Street analysts are closely watching a jury trial in New York over medical problems associated with Fosamax, a drug from Merck... It is the first of about 900 state and federal cases pending against Merck in which plaintiffs claim that taking Fosamax caused them to develop a rare problem called osteonecrosis of the jaw.	New York Times
Aug 31, 2009	Keeping genes out of terrorists' hands: Gene-synthesis industry at odds over how to screen DNA orders. QUOTE: A standards war is brewing in the gene-synthesis industry. At stake is the way that the industry screens orders for hazardous toxins and genes	Nature
Aug 26, 2009	Study Finds Radiation Risk for Patients QUOTE: At least four million Americans under age 65 are exposed to high doses of radiation each year from medical imaging tests, according to a new study...	New York Times
Aug 24, 2009	Research Trove: Patients’ Online Data QUOTE: Several private companies are now collecting patient data and genetic information online to use in recruiting patients for clinical trials, conducting research internally or to sell to drug and biotechnology companies.	New York Times
Aug 19, 2009	Report: HPV vaccine may be going to the wrong women QUOTE: some doctors now question whether the [HPV] vaccine has been overpromoted to affluent women who need it least instead of patients most at risk of dying from the disease.	USA TODAY
Aug 19, 2009	Obama endangering developing countries' access to affordable drugs, activists charge QUOTE: [activists] say the problem may lie in the administration's reluctance to confront the giant pharmaceutical companies at a time when the companies are crucial allies in President Obama's struggle to revamp the U.S. healthcare system.
Aug 18, 2009	Senator Moves to Block Medical Ghostwriting QUOTE: A growing body of evidence suggests that doctors at some of the nation’s top medical schools have been attaching their names and lending their reputations to scientific papers that were drafted by ghostwriters working for drug companies...	New York Times
Aug 18, 2009	Live From the O.R.: The problems with broadcasting surgeries as they happen. QUOTE: Combining education with entertainment and patient care with promotion, live telesurgery is a fixture at surgical conferences and marketing campaigns by hospitals and medical device manufacturers	Slate
Aug 17, 2009	Diabetes Case Shows Pitfalls of Treatment Rules QUOTE: setting [healthcare] guidelines that are good for every patient, it turns out, can get messy, with some experts warning that a big national plan of this sort poses risks.	New York Times
Aug 13, 2009	Senators Investigate Hospital Purchasing QUOTE: Senators from committees like finance, judiciary and aging are investigating the practices of companies that represent big networks of hospitals, nursing homes and other institutions. These group purchasing organizations select “preferred” manufacturers and negotiate the prices of medical products, which are a closely held secret.	New York Times
Aug 13, 2009	Privacy Regulations Bedevil Medical Social Media Efforts QUOTE: To truly participate in social media, healthcare organizations need to allow other people to leave comments on the organizations' content. But that's difficult to reconcile with HIPAA and other government privacy regulations...	InformationWeek
Aug 11, 2009	Salvia on Schedule: Law, Medicine and a Hallucinogen: Scheduling the mind-altering herb as a controlled substance could slow medical research QUOTE: As the source of the most powerful natural hallucinogen known, salvia is drawing scrutiny from U.S. authorities who want to restrict this Mexican herb... But neuro­scientists worry that controlling it before studies have determined its safety profile is premature and could hamper research of the drug's medicinal value.	Scientific American
Aug 05, 2009	Studies Question Using Cement for Spine Injuries QUOTE: Two new studies cast serious doubt on a widely used and expensive treatment for painful fractures in the spine.	New York Times
Aug 04, 2009	Medical Papers by Ghostwriters Pushed Therapy QUOTE: Newly unveiled court documents show that ghostwriters paid by a pharmaceutical company played a major role in producing 26 scientific papers backing the use of hormone replacement therapy in women, suggesting that the level of hidden industry influence on medical literature is broader than previously known.	New York Times
Aug 02, 2009	Lack of Study Volunteers Hobbles Cancer Fight ("Forty Years' War" part 4) QUOTE: There are more than 6,500 cancer clinical trials seeking adult patients, according to clinicaltrials.gov... But many will be abandoned along the way. More than one trial in five sponsored by the National Cancer Institute failed to enroll a single subject, and only half reached the minimum needed for a meaningful result Dr. [Scott] Ramsey and his colleague John Scoggins reported...	New York Times
Aug 01, 2009	Adaptive Evolution: A once-rare type of clinical trial that violates one of the sacred tenets of trial design is taking off, but is it worth the risk? QUOTE: in an increasingly common approach, a trial can be altered in various ways while it’s still in progress... Such modifications are based on a peek at interim data—which of necessity means unblinding the data before the trial’s completion.	Scientist, The (TS)
Jul 30, 2009	Does your child need ADHD drugs? (Empowered Patient) QUOTE: Does my child really need drugs for ADHD, and if so, is there a point when he or she should stop taking them?...Because drug companies tend to give samples for only the most expensive drugs, once the samples run out, you'll end up paying more than if your child had been prescribed a generic drug.	CNN (Cable News Network)
Jul 28, 2009	Perils of the professional lab rat QUOTE: Now some health researchers and bioethicists are expressing concern at the way socially and financially vulnerable people are being drawn to careers... as guinea pigs in phase I clinical trials.	New Scientist
Jul 26, 2009	Lawmakers Seek to Curb Drug Commercials QUOTE: For some legislators and consumer advocates, the [drug] ads are a daily reminder of a health care system run amok. Critics contend that drug ads are intended to prompt people to diagnose themselves with chronic quality-of-life problems like insomnia or restless leg syndrome; lead people to pressure their doctors for prescriptions for expensive brand-name drugs to treat these conditions; and steer people away from cheaper generic pills.	New York Times

263 Articles and Resources. Go to:  [Next 50]   [End]

Please send your comments and suggestions to the Webmaster. © copyright 1999-2009, Fairness.com LLC.
"Fairness.com" and "Life isn't fair... but we're working on it" are service marks of Fairness.com LLC. All rights reserved.